<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00493597</url>
  </required_header>
  <id_info>
    <org_study_id>EC 7/5/36</org_study_id>
    <nct_id>NCT00493597</nct_id>
  </id_info>
  <brief_title>Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of in-Stent Restenosis</brief_title>
  <official_title>Blood Endothelium Progenitor Cells and Dendritic Cells as Novel Predictive Biomarkers of in-Stent Restenosis After Percutaneous Coronary Intervention.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      clinically relevant in stent restenosis occurs in 5-10% of the non-diabetic patients treated
      with a coronary bare metal stent. Recent research has identified endothelial progenitor cells
      as well as dendritic cells as components of neointima. Numerical and functional evaluation of
      endothelial progenitor and dendritic cells at the time of coronary stent implantation is
      assessed and the relation with clinical and/or angiographic restenosis at 6 months post-stent
      implantation is evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Restenosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Non-diabetic patients scheduled for PCI with a single bare metal stent in a significant de
        novo coronary lesion
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18 years old

          -  Scheduled for PCI

          -  Candidate for CABG if necessary

          -  Clinical evidence of ischemic heart disease and/or abnormal functional study

          -  New native coronary artery lesion &gt;50%-&lt;100% stenosis

          -  Lesion length&lt;30 mm, treatment with a single bare metal stent planned

          -  Reference diameter 2.5-3.5 mm

          -  Informed consent explained, red, understood and signed by the patient

        Exclusion Criteria:

          -  Pregnancy, birth or lactation period &lt;6 months ago

          -  Women of childbearing age who do not intend to use accepted anticonceptive measures or
             who wish to get pregnant

          -  Left ventricular ejection fraction &lt;30%

          -  Acute myocardial infarction (ST-elevation, Q-wave evolution or CK-MB &gt;2x upper limit
             of normal)in the past month

          -  Contra-indication to PCI

          -  Diabetes mellitus

          -  Planned drug eluting stent implantation

          -  Total occlusion (TIMI 0 or 1)

          -  Ostial localisation (&lt;3.0 mm of the coronary ostium) of the lesion

          -  Bifurcational lesion with side branch &gt;2.0 mm or side branch which will be recanalised
             at occlusion due to PCI

          -  Lesion in arterial or venous bypass or anastomosis with coronary

          -  Angiographic contra-indication to IVUS

          -  Severe renal insufficiency (creatinine clearance &lt;30 mL/')

          -  Severe hepatic insufficiency

          -  Systemic inflammatory pathology of any kind

          -  Uncorrected hyperthyreosis

          -  Hematologic or other malignancy, prior radio- or chemotherapy

          -  Severe peripheral artery disease (accesproblem via groin)

          -  Use of corticostero√Øds or immune suppression therapy

          -  Contrastallergy

          -  Life expectancy &lt;1 year

          -  Participation in other clinical study which has not ended yet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven E Haine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Antwerpen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven E Haine, MD</last_name>
    <phone>0032.3.821.42.81</phone>
    <email>Steven.Haine@uza.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myriam Michiels, Nurse</last_name>
    <phone>0032.3.821.33.04</phone>
    <email>Myriam.Michiels@uza.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven E Haine, MD</last_name>
      <phone>0032.3.821.42.81</phone>
      <email>Steven.Haine@uza.be</email>
    </contact>
    <investigator>
      <last_name>Steven E Haine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris Vrints, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johan M Bosmans, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Claeys, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hielko P Miljoen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2007</study_first_submitted>
  <study_first_submitted_qc>June 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2007</study_first_posted>
  <last_update_submitted>January 30, 2009</last_update_submitted>
  <last_update_submitted_qc>January 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Haine, Steven, MD</name_title>
    <organization>University Hospital of Antwerp</organization>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Restenosis</keyword>
  <keyword>EPC</keyword>
  <keyword>DC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

